302 related articles for article (PubMed ID: 30236142)
1. Integrated genomic analyses in PDX model reveal a cyclin-dependent kinase inhibitor Palbociclib as a novel candidate drug for nasopharyngeal carcinoma.
Hsu CL; Lui KW; Chi LM; Kuo YC; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Huang MY; Lai YR; Yeh YM; Fan HC; Lin AC; Lu YJ; Hsieh CH; Chang KP; Tsang NM; Wang HM; Chang AY; Chang YS; Li HP
J Exp Clin Cancer Res; 2018 Sep; 37(1):233. PubMed ID: 30236142
[TBL] [Abstract][Full Text] [Related]
2. Identification of aberrant cell cycle regulation in Epstein-Barr virus-associated nasopharyngeal carcinoma by cDNA microarray and gene set enrichment analysis.
Zhang W; Zeng Z; Zhou Y; Xiong W; Fan S; Xiao L; Huang D; Li Z; Li D; Wu M; Li X; Shen S; Wang R; Cao L; Tang K; Li G
Acta Biochim Biophys Sin (Shanghai); 2009 May; 41(5):414-28. PubMed ID: 19430707
[TBL] [Abstract][Full Text] [Related]
3. Nasopharyngeal carcinoma patient-derived xenograft mouse models reveal potential drugs targeting cell cycle, mTOR, and autophagy pathways.
Li HP; Huang CY; Lui KW; Chao YK; Yeh CN; Lee LY; Huang Y; Lin TL; Kuo YC; Huang MY; Fan HC; Lin AC; Hsieh CH; Chang KP; Lin CY; Wang HM; Chao M; Liu JS; Chang YS; Hsu CL
Transl Oncol; 2023 Dec; 38():101785. PubMed ID: 37713975
[TBL] [Abstract][Full Text] [Related]
4. Genomic Analysis of Nasopharyngeal Carcinoma Reveals TME-Based Subtypes.
Zhang L; MacIsaac KD; Zhou T; Huang PY; Xin C; Dobson JR; Yu K; Chiang DY; Fan Y; Pelletier M; Wang Y; Jaeger S; Krishnamurthy Radhakrishnan V; JeBailey L; Skewes-Cox P; Zhang J; Fang W; Huang Y; Zhao H; Zhao Y; Li E; Peng B; Huang A; Dranoff G; Hammerman PS; Engelman J; Bitter H; Zeng YX; Yao Y
Mol Cancer Res; 2017 Dec; 15(12):1722-1732. PubMed ID: 28851814
[TBL] [Abstract][Full Text] [Related]
5. Epstein-Barr virus BALF3 mediates genomic instability and progressive malignancy in nasopharyngeal carcinoma.
Chiu SH; Wu CC; Fang CY; Yu SL; Hsu HY; Chow YH; Chen JY
Oncotarget; 2014 Sep; 5(18):8583-601. PubMed ID: 25261366
[TBL] [Abstract][Full Text] [Related]
6. Genetic Aberrations in the CDK4 Pathway Are Associated with Innate Resistance to PD-1 Blockade in Chinese Patients with Non-Cutaneous Melanoma.
Yu J; Yan J; Guo Q; Chi Z; Tang B; Zheng B; Yu J; Yin T; Cheng Z; Wu X; Yu H; Dai J; Sheng X; Si L; Cui C; Bai X; Mao L; Lian B; Wang X; Yan X; Li S; Zhou L; Flaherty KT; Guo J; Kong Y
Clin Cancer Res; 2019 Nov; 25(21):6511-6523. PubMed ID: 31375512
[TBL] [Abstract][Full Text] [Related]
7. Application of a patient-derived xenograft model in cytolytic viral activation therapy for nasopharyngeal carcinoma.
Hsu CL; Kuo YC; Huang Y; Huang YC; Lui KW; Chang KP; Lin TL; Fan HC; Lin AC; Hsieh CH; Lee LY; Wang HM; Li HP; Chang YS
Oncotarget; 2015 Oct; 6(31):31323-34. PubMed ID: 26416517
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of PIN1 Enhances Cancer Growth and Aggressiveness with Cyclin D1 Induction in EBV-Associated Nasopharyngeal Carcinoma.
Xu M; Cheung CC; Chow C; Lun SW; Cheung ST; Lo KW
PLoS One; 2016; 11(6):e0156833. PubMed ID: 27258148
[TBL] [Abstract][Full Text] [Related]
9. Clinical Benefit in Response to Palbociclib Treatment in Refractory Uterine Leiomyosarcomas with a Common
Elvin JA; Gay LM; Ort R; Shuluk J; Long J; Shelley L; Lee R; Chalmers ZR; Frampton GM; Ali SM; Schrock AB; Miller VA; Stephens PJ; Ross JS; Frank R
Oncologist; 2017 Apr; 22(4):416-421. PubMed ID: 28283584
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive genomic profiling of different subtypes of nasopharyngeal carcinoma reveals similarities and differences to guide targeted therapy.
Ali SM; Yao M; Yao J; Wang J; Cheng Y; Schrock AB; Chirn GW; Chen H; Mu S; Gay L; Elvin JA; Suh J; Miller VA; Stephens PJ; Ross JS; Wang K
Cancer; 2017 Sep; 123(18):3628-3637. PubMed ID: 28581676
[TBL] [Abstract][Full Text] [Related]
11. miR-663 promotes NPC cell proliferation by directly targeting CDKN2A.
Liang S; Zhang N; Deng Y; Chen L; Zhang Y; Zheng Z; Luo W; Lv Z; Li S; Xu T
Mol Med Rep; 2017 Oct; 16(4):4863-4870. PubMed ID: 28765905
[TBL] [Abstract][Full Text] [Related]
12. Frequent genetic aberrations in the cell cycle related genes in mucosal melanoma indicate the potential for targeted therapy.
Xu L; Cheng Z; Cui C; Wu X; Yu H; Guo J; Kong Y
J Transl Med; 2019 Jul; 17(1):245. PubMed ID: 31358010
[TBL] [Abstract][Full Text] [Related]
13. Whole-genome profiling of nasopharyngeal carcinoma reveals viral-host co-operation in inflammatory NF-κB activation and immune escape.
Bruce JP; To KF; Lui VWY; Chung GTY; Chan YY; Tsang CM; Yip KY; Ma BBY; Woo JKS; Hui EP; Mak MKF; Lee SD; Chow C; Velapasamy S; Or YYY; Siu PK; El Ghamrasni S; Prokopec S; Wu M; Kwan JSH; Liu Y; Chan JYK; van Hasselt CA; Young LS; Dawson CW; Paterson IC; Yap LF; Tsao SW; Liu FF; Chan ATC; Pugh TJ; Lo KW
Nat Commun; 2021 Jul; 12(1):4193. PubMed ID: 34234122
[TBL] [Abstract][Full Text] [Related]
14. Cyclin D1 overexpression supports stable EBV infection in nasopharyngeal epithelial cells.
Tsang CM; Yip YL; Lo KW; Deng W; To KF; Hau PM; Lau VM; Takada K; Lui VW; Lung ML; Chen H; Zeng M; Middeldorp JM; Cheung AL; Tsao SW
Proc Natl Acad Sci U S A; 2012 Dec; 109(50):E3473-82. PubMed ID: 23161911
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic evaluation of palbociclib and its compatibility with other chemotherapies for primary and recurrent nasopharyngeal carcinoma.
Xue Z; Lui VWY; Li Y; Jia L; You C; Li X; Piao W; Yuan H; Khong PL; Lo KW; Cheung LWT; Lee VHF; Lee AWM; Tsao SW; Tsang CM
J Exp Clin Cancer Res; 2020 Nov; 39(1):262. PubMed ID: 33243298
[TBL] [Abstract][Full Text] [Related]
16. Synergistic anti-cancer activity of CDK4/6 inhibitor palbociclib and dual mTOR kinase inhibitor MLN0128 in pRb-expressing ER-negative breast cancer.
Yamamoto T; Kanaya N; Somlo G; Chen S
Breast Cancer Res Treat; 2019 Apr; 174(3):615-625. PubMed ID: 30607633
[TBL] [Abstract][Full Text] [Related]
17. Berberine inhibits the proliferation of human nasopharyngeal carcinoma cells via an Epstein-Barr virus nuclear antigen 1-dependent mechanism.
Wang C; Wang H; Zhang Y; Guo W; Long C; Wang J; Liu L; Sun X
Oncol Rep; 2017 Apr; 37(4):2109-2120. PubMed ID: 28259949
[TBL] [Abstract][Full Text] [Related]
18. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
19. NAP1L1 targeting suppresses the proliferation of nasopharyngeal carcinoma.
Liu Y; Li X; Zhang Y; Tang Y; Fang W; Liu X; Liu Z
Biomed Pharmacother; 2021 Nov; 143():112096. PubMed ID: 34563951
[TBL] [Abstract][Full Text] [Related]
20. Quantitation of DNA methylation in Epstein-Barr virus-associated nasopharyngeal carcinoma by bisulfite amplicon sequencing.
Zhao W; Mo Y; Wang S; Midorikawa K; Ma N; Hiraku Y; Oikawa S; Huang G; Zhang Z; Murata M; Takeuchi K
BMC Cancer; 2017 Jul; 17(1):489. PubMed ID: 28716111
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
